Centre for Global Health Research, Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.
Global Vaccine Epidemiology and Modeling Department, Sanofi Pasteur, Lyon, France.
J Infect Dis. 2020 Oct 7;222(Suppl 7):S577-S583. doi: 10.1093/infdis/jiz059.
Respiratory syncytial virus-associated acute respiratory infection (RSV-ARI) constitutes a substantial disease burden in older adults aged ≥65 years. We aimed to identify all studies worldwide investigating the disease burden of RSV-ARI in this population. We estimated the community incidence, hospitalization rate, and in-hospital case-fatality ratio (hCFR) of RSV-ARI in older adults, stratified by industrialized and developing regions, using data from a systematic review of studies published between January 1996 and April 2018 and 8 unpublished population-based studies. We applied these rate estimates to population estimates for 2015 to calculate the global and regional burdens in older adults with RSV-ARI in the community and in hospitals for that year. We estimated the number of in-hospital deaths due to RSV-ARI by combining hCFR data with hospital admission estimates from hospital-based studies. In 2015, there were about 1.5 million episodes (95% confidence interval [CI], .3 million-6.9 million) of RSV-ARI in older adults in industrialized countries (data for developing countries were missing), and of these, approximately 14.5% (214 000 episodes; 95% CI, 100 000-459 000) were admitted to hospitals. The global number of hospital admissions for RSV-ARI in older adults was estimated at 336 000 hospitalizations (uncertainty range [UR], 186 000-614 000). We further estimated about 14 000 in-hospital deaths (UR, 5000-50 000) related to RSV-ARI globally. The hospital admission rate and hCFR were higher for those aged ≥65 years than for those aged 50-64 years. The disease burden of RSV-ARI among older adults is substantial, with limited data from developing countries. Appropriate prevention and management strategies are needed to reduce this burden.
呼吸道合胞病毒相关的急性呼吸道感染(RSV-ARI)在≥65 岁的老年人中构成了相当大的疾病负担。我们旨在确定全球所有研究 RSV-ARI 在该人群中疾病负担的研究。我们使用 1996 年 1 月至 2018 年 4 月发表的研究的系统综述数据以及 8 项未发表的基于人群的研究,估计了工业化和发展中地区老年人中 RSV-ARI 的社区发病率、住院率和住院病死率(hCFR),并进行了分层。我们将这些速率估计应用于 2015 年的人群估计值,以计算当年社区和医院中患有 RSV-ARI 的老年人的全球和区域负担。我们将 hCFR 数据与基于医院的研究中的住院估计值相结合,计算了因 RSV-ARI 导致的住院死亡人数。2015 年,工业化国家约有 150 万例(95%置信区间 [CI],30 万至 690 万)老年人患有 RSV-ARI(发展中国家的数据缺失),其中约 14.5%(214000 例;95%CI,100000-459000)住院。全球老年人因 RSV-ARI 住院的人数估计为 336000 例住院(不确定性范围 [UR],186000-614000)。我们进一步估计全球约有 14000 例因 RSV-ARI 住院的死亡病例(UR,5000-50000)。年龄≥65 岁的患者住院率和 hCFR 高于 50-64 岁的患者。老年人中 RSV-ARI 的疾病负担相当大,而来自发展中国家的数据有限。需要采取适当的预防和管理策略来减轻这一负担。